News & Updates

New drug applications approved by US FDA as of 16-31 December 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with icosapent ethyl did not reduce the rate of hospitalization or mortality among patients with SARS-CoV-2 infection, according to results of the PREPARE IT-2* trial presented at AHA 2021.

A delayed dose reduction of tacrolimus, along with induction of basiliximab, helps suppress kidney injury in liver transplant recipients, as opposed to standard-dose tacrolimus, a recent study has found. Such benefits come with no excess risk of rejection, graft loss, or death.

Receipt of a booster dose of the BNT162b2 mRNA vaccine is tied to a reduced risk of testing positive for SARS-CoV-2, according to results of a study from Israel.

Children with asthma who are infected with SARS-CoV-2 virus are at an increased risk of hospitalization, especially those whose asthma is poorly controlled, compared with children without asthma, according to data from the EAVE II* study.

The benefits in terms of prolonged disease-free survival (DFS) and reduced risk of recurrence with ovarian function suppression (OFS) persisted over 12–13 years in premenopausal women with hormone receptor-positive (HR+) breast cancer, according to new data from the TEXT and SOFT randomized trials presented at SABCS 2021.

The threat of Omicron is real, with scientists working at breakneck speed to better understand its virulence and potential ability to evade currently approved vaccines.